<DOC>
	<DOCNO>NCT01245816</DOCNO>
	<brief_summary>The purpose phase III study evaluate safety efficacy combination eflornithine sulindac compare single agent sulindac eflornithine reduce number polyp patient familial adenomatous polyposis ( FAP ) .</brief_summary>
	<brief_title>A Trial Low Dose Sulindac Combined With Eflornithine Patients With Familial Adenomatous Polyposis ( FAP )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Adenomatous Polyposis Coli</mesh_term>
	<mesh_term>Sulindac</mesh_term>
	<mesh_term>Eflornithine</mesh_term>
	<criteria>Diagnosis phenotypic Familial Adenomatous Polyposis ( FAP ) colorectum base meeting criterion one two group : Group 1Greater 100 adenomatous colorectal polyp prior age 40 . Group 2Greater 10 adenomatous polyp age &lt; 40 great 25 polyp age &gt; 40 ; combine dominant family history genotype : More 100 polyp firstdegree relative ; More 25 polyp 2 relative 2 generation , include firstdegree family member ; Genetic diagnosis relative ; Genetic diagnosis vitro synthesize truncate protein similar assay . No colorectal surgery prior colon surgery polyposis least 1 year prior ( total abdominal colectomy ilealrectal anastomosis , total proctocolectomy ilea pouchanal reconstruction . Baseline endoscopy 1 . If prior colorectal surgery , least 3 polyp cluster ≥ 2 mm diameter ; 2 . If rectum situ assess , baseline rectal segment endoscopy document 3 rectal polyp least 2 mm diameter define cluster and/or least 6 polyp , ≥ 2 mm diameter , distal 10 cm rectum 3 . If ileal pouch neorectum place , 3 pouch polyp cluster ≥ 2 mm diameter , least 6 polyp , ≥ 2 mm diameter , distal 10 cm pouch . 4 . Clinical/pathological grade duodenal polyp utilize Spigelman Classification . Hematopoietic : significant hematologic dysfunction ; WBC ≥3,000/mm3 ; platelet count ≥100,000/mm3 ; hemoglobin ≥10g/dL ; know prior clinical coagulopathy . Hepatic : bilirubin ≤ 1.5 time ULN ; AST ALT ≤ 1.5 time ULN ; Alkaline phosphatase ≤ 1.5 time ULN . Renal : No significant renal dysfunction ; creatinine ≤ 1.5 time ULN . Hearing : clinically significant hearing loss affect everyday life . Not pregnant nursing . Negative serum pregnancy test female childbearing potential . Absence gross blood stool . Fertile patient must use effective contraception . Stool occult blood either negative minimal ( 1+ ) . No prior hypersensitivity cyclooxygenase2 inhibitor , sulfonamide , NSAIDs , salicylates ; NSAID associate symptom gastritis . No discrete gastric duodenal ulcer great 5 mm within past year except Helicobacter pylorirelated peptic ulcer disease treat successfully antibiotic ( document endoscopy . No invasive malignancy within past 5 year except stage I II colon rectal cancer resect nonmelanomatous skin cancer . No significant medical psychiatric problem would preclude study participation . No chronic adrenocorticosteroids . No prior pelvic irradiation . At least 3 month since prior investigational agent . Patients may receive plan receive corticosteroid . Concomitant NSAID use outside study may exceed 4 day per month . Use 81 mg daily aspirin 650 mg aspirin week . No concurrent warfarin , fluconazole , lithium . Must willing able sign inform consent . High Risk cardiovascular disease include clinical diabetes mellitus ( Type I II ) require glycemic medication ; Prior personal history cardiovascular disease , two follow hypertension use antihypertensive medication , hyperlipidemia use lipidlowering medication current smoker . Hearing loss affect everyday life hear aid require .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>colon polyp</keyword>
</DOC>